Importance Tumor size larger than 4 cm is accepted as an indication for adjuvant
chemotherapy in patients with node-negative non–small cell lung cancer (NSCLC) …

Objective The role of adjuvant therapy in small bowel adenocarcinoma (SBA), a rare
malignancy with a poor prognosis, is controversial. The purpose of this article is to …

Background Adjuvant chemotherapy (AC) is recommended since 2004 for patients with a
completely resected non-small cell lung cancer (NSCLC). Indeed, several randomized …

Background Intrapulmonary lymph nodes (LNs, stations 11–14) are usually omitted in
postoperative pathological examination. Some non‐small cell lung cancer (NSCLC) patients …

Objective Adjuvant chemotherapy prolongs survival in patients with non–small cell lung
cancer with N1 disease or tumors larger than 4 cm. Patients with T3N0 disease due to chest …

Background Since randomised clinical trials demonstrated a survival benefit of adjuvant
chemotherapy (AC) following curative-intent lung surgery, AC has been implemented as a …

Background Primary lung cancer that invades the chest wall is classified as T3 regardless of
the depth of invasion. This study assessed the prognostic impact of pathologically confirmed …

Background Surgical resection is the main treatment for early-stage non-small cell lung
cancer (NSCLC), but recurrence remains a concern. Adjuvant chemotherapy has been …

Background Nowadays, cancer and cardiac diseases are two of the most causes of death,
so cancer treatment‐related cardiac death cannot be ignored. For lung cancer, chest …

The evidence for stereotactic body radiotherapy (SBRT) is meagre for patients with clinical
T3-4N0M0 non-small cell lung cancer (8th Edition of the Union for International Cancer …